<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87274">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01803451</url>
  </required_header>
  <id_info>
    <org_study_id>05-09-28-01</org_study_id>
    <nct_id>NCT01803451</nct_id>
  </id_info>
  <brief_title>Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass</brief_title>
  <acronym>GLP-1</acronym>
  <official_title>The Role of Glucagon Like Peptide-1 in Glucose Metabolism and Weight Loss Following Gastric Bypass Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this project is to understand the mechanisms by which gastric bypass
      surgery improves glucose metabolism.

      The central hypothesis guiding this project is that the reconfiguration of intestinal
      transit with the Roux-en-Y will increase the release of insulinotropic GI hormones, termed
      incretins that improve insulin secretion and glucose metabolism. The study is divided into
      three specific aims.

        1. To determine the role of incretin hormones on insulin secretion in patients with
           gastric bypass surgery using intravenous-oral hyperglycemic clamp.

        2. To compare incretin effect and glucose tolerance among patient who suffer from
           hypoglycemia after RYGB and asymptomatic surgical and non-surgical individuals.

        3. To quantify the contribution of GLP-1 to incretin effect enhancement following surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2005</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 0</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject)</study_design>
  <primary_outcome>
    <measure>The investigator measure glucose, islet and GI hormonal levels in response to meal ingestion as a composite measure and the percentage of contribution of GLP-1 contribution to postprandial insulin levels will also be calculated</measure>
    <time_frame>up to  1 year (10 sessions)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Post-bariatric Surgery</condition>
  <arm_group>
    <arm_group_label>hyperglycemic clamp-Meal tolerance test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>these studies are to evaluate the effect of exendin-9 on insulin secretion before and after meal ingestion in patients after bariatric surgeries compared to non-surgical controls</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Labeled meal tolerance test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The effect of GLP-1 receptor blockade on glucose tolerance and glucose kinetics are evaluated in the group patients with bariatric surgery vs. nonsurgical using exendin-9-39 infusion during one of the the 2-day dual tracer studies of meal tolerance test</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exendin-(9-39)</intervention_name>
    <description>hyperglycemic clamp-meal tolerance test is designed to assess insulin secretion before and after meal ingestion</description>
    <arm_group_label>hyperglycemic clamp-Meal tolerance test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exendin -(9-39)</intervention_name>
    <description>2-day meal tolerance tests with labeled oral and IV glucose using exendin-(9-39) infusion are designed to evaluate the role of GLP-1 signaling on glucose tolerance and glucose kinetics.</description>
    <arm_group_label>Labeled meal tolerance test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18-65

          -  healthy control without diabetes or active organ disease

          -  Individuals with bariatric surgery

          -  recurrent hypoglycemia post gastric bypass

        Exclusion Criteria:

          -  pregnancy

          -  significant anemia

          -  diabetes currently unless pre-op for bariatric surgery procedure

          -  GI obstruction
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marzieh Salehi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leslie M Baum, RN</last_name>
    <phone>513-558-0201</phone>
    <email>leslie.baum@uc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marzieh Salehi, MD</last_name>
    <phone>513-558-0001</phone>
    <email>marzieh.salehi@uc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie M Baum, RN</last_name>
      <phone>513-558-0201</phone>
      <email>leslie.baum@uc.edu</email>
    </contact>
    <investigator>
      <last_name>Marzieh Salehi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>March 2, 2013</lastchanged_date>
  <firstreceived_date>February 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Marzieh Salehi</investigator_full_name>
    <investigator_title>Marzieh Salehi MD, MS, FACP  Assistant Professor of Medicine, University of Cincinnati College of Medicine Division of Endocrinology, Diabetes and Metabolism</investigator_title>
  </responsible_party>
  <keyword>gastric bypass</keyword>
  <keyword>glucose metabolism</keyword>
  <keyword>hypoglycemia</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
